DUBLIN, September 8, 2017 /PRNewswire/ --
The "Global Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts" report has been added to Research and Markets' offering.
The report provides a detailed understanding and analysis of how and why companies enter Diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.
This report provides details of the latest Diagnostics agreements announced in the life sciences since 2010.
The report takes the reader through a comprehensive review Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Diagnostics partnering deals.
The report presents financial deal term values for Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Diagnostics partnering field; both the leading deal values and most active Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 3,600 online deal records of actual Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
The Global Diagnostics Partnering 2010-2017 report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading companies.
- Comprehensive directory of diagnostic deals since 2010
- Diagnostic contract documents
- Diagnostic agreement terms
- Diagnostic agreement structure
- Top diagnostic deals by value
- Most active diagnostic dealmakers
This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering:
- Companion Diagnostics
- Imaging
- CT
- Endoscope
- Molecular and nuclear
- MRI
- Ultrasound
- X-ray
- PET
- SPECT
- Angiography
- Fluroscopy
- Mammography
- In vitro diagnostics
- Molecular diagnostics
- Prognostics
- Theranostics
In Global Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Diagnostics dealmaking
Chapter 3 - Leading Diagnostics deals
Chapter 4 - Most active Diagnostics dealmakers
Chapter 5 - Diagnostics contracts dealmaking directory
Chapter 6 - Diagnostics dealmaking by technology type
Chapter 7 - Partnering resource center
For more information about this report visit https://www.researchandmarkets.com/research/wcsvmc/global
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article